Continuing Education in Psoriasis and Psoriatic Arthritis
Available Activities
Psoriasis Prime Time: The Role of TYK Inhibition in Psoriasis
Time
30 Min
Credits
0.5
Start Now!
Case Consult: Psoriasis With Scalp Involvement in a Patient With Skin of Color
Time
30 Min
Credits
0.5
Start Now!
Psoriasis Prime Time: TYK Inhibition in Hard-to-Treat Psoriasis
Time
30 Min
Credits
0.5
Start Now!
Case Consult: A Case of Psoriasis in a Patient with Depression and History of Malignancy
Time
30 Min
Credits
0.5
Start Now!
Incorporating Novel Therapies in the Management of Psoriasis: The Latest Efficacy, Safety, and Patient Outcomes
Time
30 Min
Credits
0.5
Start Now!
View Additional Resources
Psoriasis Newsfeed
Reappraising the Use of Systemic Immunomodulators for Psoriasis and Eczema in the Military
December 1, 2024
Russell A, Williamson S, Rosenberg A, Cho S. Reappraising the Use of Systemic Immunomodulators for Psoriasis and Eczema in the Military. Mil Med. 2024;189(11-12):e2374-e2381.
The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: A systematic review
August 16, 2024
Vangilbergen M, Stockman A, Van De Velde A, Garmyn M, Punie K, Hillary T. The role of interleukin-17 and interleukin-23 inhibitors in the development, progression, and recurrence of cancer: A systematic review. JAAD Int. 2024;17:71-79.
Psoriasis health indicator report
September 23, 2024
Gondo GC, Eakin G, Van Voorhees A, et al. Psoriasis health indicator report. National Psoriasis Foundation. Published January 2024.
Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials
June 30, 2024
Korman NJ, Warren RB, Bagel J, et al. Deucravacitinib onset of action and maintenance of response in phase 3 plaque psoriasis trials. J Dermatolog Treat. 2024;35(1):2371045.
Read More
